Lausanne, Switzerland — March 13, 2026 — Leads & Copy —
AC Immune SA (NASDAQ: ACIU) has released its financial results for the full year 2025 and provided a corporate update, reporting progress in its clinical programs and pipeline development.
According to Dr. Andrea Pfeifer, CEO of AC Immune SA, the company made significant progress toward precision prevention of neurodegenerative diseases in 2025. Interim data from the VacSYn trial of ACI-7104 suggests the potential for active immunotherapies as disease-modifying treatments, which could slow or prevent neuronal damage. Additionally, the company’s Morphomer small-molecule therapeutics target intracellular mechanisms, enabling intervention at the earliest stages of disease. ACI-19764, a brain-penetrant NLRP3 inhibitor, has entered a Phase 1 trial.
The company reported positive interim safety and efficacy results from Part 1 of the Phase 2 VacSYn trial of ACI-7104 in early Parkinson’s disease (PD). Results suggest that targeting underlying α-synuclein pathology with an active immunotherapy may slow the rate of progression of Parkinson’s disease. The treatment has a clear safety profile with no clinically relevant safety issues reported to date. Targets were met for immunogenicity (100% responder rate), pharmacodynamic effect, target engagement, and clinical assessments. Final data from Part 1 of the study is expected in mid-2026.
AC Immune is progressing its Morphomer small molecule Tau aggregation inhibitors for the potential treatment of Alzheimer’s disease (AD) and other neurodegenerative diseases. Investigational New Drug (IND)-enabling studies are expected to begin in H1 2026.
The first participants have been dosed in a Phase 1 clinical trial of ACI-19764, a brain-penetrant small molecule targeting the NLRP3 inflammasome (NCT07463196). NLRP3 inhibitors have the potential to intervene at the earliest stages of disease in neurodegenerative conditions, including AD, PD, amyotrophic lateral sclerosis (ALS) and frontotemporal dementia. Potential additional indications include inflammatory disorders, cancer, cardiovascular disease, metabolic disorders, skin inflammatory diseases and rare genetic syndromes of autoimmunity. ACI-19764 is an orally available, brain-penetrant NLRP3 inhibitor and a major addition to AC Immune’s growing intracellular targeting pipeline.
Following a strategic review by executive management, AC Immune has sharpened investment on its most important assets, which include the three clinical-stage active immunotherapy programs ACI-7104, ACI-24 and ACI-35, and promising small molecule programs targeting NLRP3, Tau and α-synuclein. The company reduced its workforce by around 30% and extended its cash for operations to the end of Q3 2027.
Clinical results from the completed Phase 1b/2a trial of active immunotherapy ACI-35 (JNJ-2056) partnered with Janssen Pharmaceuticals, Inc., a Johnson & Johnson company, have been published in eBioMedicine. Preclinical research demonstrating the in vivo activity of a vectorized (AAV9) anti-TDP-43 monoclonal antibody in a model of ALS/FTD, has been published in Molecular Therapy. First-in-class positron emission tomography (PET) tracers for imaging TDP-43 pathology in the brain, including ACI-19626, have been published in Nature Communications. The company’s therapeutic and diagnostic programs were featured in presentations at AD/PD™ 2025.
Prof. Catherine Mummery, a neurologist and expert in dementia clinical trials, has been appointed as Chair of Ac Immune’s Clinical Advisory Board (CAB).
Anticipated milestones for 2026 include final data from Part 1 of the Phase 2 VacSYn trial in PD (H2 2026), interim results from ABATE Phase 2 trial after reaching 12-month treatment timepoint in the AD3 cohort (H1 2026), results from Phase 1 trial of ACI-19764 in healthy volunteers (H2 2026), lead declaration and initiation of IND-enabling studies for Morphomer-Tau aggregation inhibitors (H1 2026), and lead declaration for Morphomer α-synuclein aggregation inhibitor (H1 2026).
The Company had total cash resources of CHF 91.4 million as of December 31, 2025, compared to total cash resources of CHF 165.5 million as of December 31, 2024. The Company’s cash balance provides sufficient capital resources into Q3 2027, assuming no other milestones.
The Company recorded CHF 3.6 million in contract revenues for the year ended December 31, 2025, compared with CHF 27.3 million in the prior year. R&D expense decreased by CHF 6.1 million for the year ended December 31, 2025 to CHF 56.4 million. G&A expenses decreased by CHF 1.1 million for the year ended December 31, 2025, to CHF 16.1 million. The Company reported a net loss after taxes of CHF 70.5 million for the year ended December 31, 2025, compared with a net loss of CHF 50.9 million for the prior year.
For the full year 2026, the Company expects its total cash expenditure to be in the range of CHF 55-65 million.
AC Immune SA is focused on precision prevention for neurodegenerative diseases. The Company’s two clinically validated technology platforms, SupraAntigen® and Morphomer®, fuel its pipeline. AC Immune has a track record of securing strategic partnerships with leading global pharmaceutical companies, resulting in substantial non-dilutive funding to advance its proprietary programs and >$4.5 billion in potential milestone payments plus royalties.
Source: AC Immune SA
